Clinical Trials
Search Form
Disease Site | Trial | Trial Description | Trial Status Sort descending | Lead Cooperative Group |
---|---|---|---|---|
Ovarian | MITO 25.1 |
A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel- |
Closed to Recruitment | MITO |
Ovarian | PMHC – eVolve-1 / OZM-060 |
A Proof of Concept, Multi-centre, Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on PARP Inhibitor in Ovarian Cancer |
Closed to Recruitment | PMHC |
Ovarian | GOG0252 |
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
Closed to Recruitment | GOG-F |
Ovarian | GOG0262 |
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
Closed to Recruitment | |
Ovarian | ICON8/ICON8B |
An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer |
Closed to Recruitment | NCRI |
Ovarian | GOG0281 |
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer |
Closed to Recruitment | GOG-F |
Ovarian | ANITA/ ENGOT-Ov41/ GEICO 69-O |
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months |
Closed to Recruitment | GEICO |
Ovarian | iPocc |
IntraPeritoneal therapy for Ovarian Cancer with Carboplatin (GOTIC-001 / JGOG3019) |
Closed to Recruitment | GOTIC |
Ovarian | KGOG 3046/ TRU-D |
A phase II study of neoadjuvant chemotherapy plus tremelimumab and durvalumab in advanced-stage ovarian cancer |
Closed to Recruitment | KGOG |
Ovarian | FIRST-ENGOT-Ov44 (ENGOT/GCIG/Tesaro) |
A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer |
Closed to Recruitment | GINECO |
Ovarian | CCTG OV.25, STICS and STONES |
A randomized phase II double-blind placebo-controlled trial of Acetylsalicylic acid (ASA) in chemoprevention of ovarian cancer in women with BRCA1/2 mutations |
Closed to Recruitment | CCTG |
Ovarian | PMHC – NEO / OZM-058 |
A Phase II, Open-Label, Randomized, Multi-Centre Study of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer |
Closed to Recruitment | PMHC |
Ovarian | AGO-OVAR OP.7/TRUST |
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST) |
Follow Up | AGO |
Ovarian | AGO-OVAR23/DUO-O |
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib |
Follow Up | AGO |
Ovarian | MITO 16B MANGO OV2B |
A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line |
Completed | MITO |
Ovarian | CHORUS |
A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma |
Completed | NCRI |
Ovarian | Tarceva Trial EORTC 55041 |
A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. |
Completed | EORTC-GCG |
Ovarian | AGO – OVAR OP.3 (LION) |
Lymphadenectomy In Ovarian Neoplasms |
Completed | AGO |
Ovarian | MOCCA |
A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas |
Completed | GCGS |
Ovarian | mEOC |
A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer. |
Completed | NCRI |